HC Wainwright Reiterates “Buy” Rating for NextCure (NASDAQ:NXTC)

NextCure (NASDAQ:NXTC)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $3.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 326.14% from the company’s previous close.

NextCure Stock Up 2.2 %

Shares of NASDAQ:NXTC traded up $0.02 during trading on Monday, reaching $0.70. 24,070 shares of the company traded hands, compared to its average volume of 83,291. The firm has a market capitalization of $19.72 million, a PE ratio of -0.34 and a beta of 0.71. The company’s 50 day moving average is $0.77 and its two-hundred day moving average is $1.08. NextCure has a 52 week low of $0.66 and a 52 week high of $2.57.

NextCure (NASDAQ:NXTC) last released its earnings results on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.07). As a group, research analysts anticipate that NextCure will post -1.87 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Tang Capital Management LLC increased its position in NextCure by 7.3% during the 4th quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock worth $540,000 after purchasing an additional 47,614 shares in the last quarter. Renaissance Technologies LLC grew its holdings in NextCure by 27.9% during the 4th quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock worth $400,000 after acquiring an additional 113,300 shares during the last quarter. Peapod Lane Capital LLC acquired a new position in NextCure in the 4th quarter valued at approximately $311,000. Geode Capital Management LLC raised its stake in shares of NextCure by 14.2% during the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock valued at $307,000 after acquiring an additional 27,812 shares during the last quarter. Finally, Citadel Advisors LLC grew its stake in shares of NextCure by 40.6% in the fourth quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after purchasing an additional 22,724 shares during the last quarter. Institutional investors and hedge funds own 42.65% of the company’s stock.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.